VIASKIN Peanut Patch Shows Strong Phase 3 VITESSE Results, With David Fleischer, MD

HCPLive spoke with David Fleischer, professor of pediatrics at Children’s Hospital Colorado, about new data from the phase 3 VITESSE trial assessing the effectiveness of VIASKIN peanut patch (VP250) for building tolerance and increasing desensitization. The study showed that 82.8% of children who received VP250, compared with 48% on placebo, increased their eliciting dose over 12 months.